Charles Allred, MD
Critical Care Medicine · Media, PANPI 1437310810
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.9% of the total across 401 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 17.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,729, more than ten times the $41 reported in 2019. Among critical care medicine clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 401 payments — averaging $23.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- AstraZeneca$2K
- Harmony Biosciences LLC$712
- Regeneron Healthcare Solutions, Inc.$585
- Insmed, Inc.$461
- Mylan Specialty L.p.$454
- plus $4K from 31 others
What the payments were for
- Food & beverage$9,30998%
- Education$1962%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 82 | $1,652 |
| AstraZeneca(2 entities) | 81 | $1,615 |
| Harmony Biosciences LLC | 20 | $712 |
| Regeneron Healthcare Solutions, Inc. | 23 | $585 |
| Insmed, Inc. | 15 | $461 |
| Mylan Specialty L.p. | 20 | $454 |
| Boehringer Ingelheim | 17 | $402 |
| Johnson & Johnson | 12 | $375 |
| Jazz Pharmaceuticals Inc. | 10 | $303 |
| Axsome Therapeutics, Inc. | 8 | $269 |
| Grifols USA, LLC | 15 | $259 |
| Verona Pharma, Inc. | 10 | $227 |
| Electromed, Inc. | 10 | $185 |
| Bayer | 4 | $174 |
| Sanofi | 6 | $165 |
| ANI Pharmaceuticals, Inc. | 5 | $160 |
| Philips North America LLC | 8 | $145 |
| Viatris Specialty LLC | 5 | $141 |
| Inspire Medical Systems, Inc. | 6 | $135 |
| Mallinckrodt Hospital Products Inc. | 5 | $117 |
| Amgen | 4 | $110 |
| Novo Nordisk | 4 | $102 |
| AbbVie | 5 | $97 |
| Sanofi-aventis U.S. LLC | 1 | $97 |
| United Therapeutics Corporation | 4 | $75 |
| Lilly USA, LLC | 3 | $74 |
| Pfizer | 3 | $68 |
| E.r. Squibb & Sons, L.L.C. | 3 | $64 |
| Merck | 3 | $61 |
| Inogen, Inc. | 2 | $49 |
| Baxter Healthcare | 1 | $39 |
| Actelion Pharmaceuticals US, Inc. | 1 | $32 |
| Resmed Corp | 1 | $24 |
| Tactile Systems Technology Inc | 1 | $24 |
| Vifor Pharma, Inc. | 1 | $23 |
| Nabriva Therapeutics, PLC | 1 | $17 |
| Paratek Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,506 in reported general payments places this provider in the 90th percentile of 354 critical care medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 113 | $94,917 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 72 | $59,756 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 59 | $28,598 |
| Spiriva RespimatTiotropium Bromide | 34 | $20,948 |
| Breo ElliptaFluticasone/Vilanterol | 40 | $20,557 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 25 | $15,218 |
| Incruse ElliptaUmeclidinium Bromide | 28 | $12,495 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 74 | $12,466 |
| SymbicortBudesonide/Formoterol Fumarate | 40 | $11,087 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 40 | $6,635 |
| Advair HfaFluticasone Propion/Salmeterol | 16 | $6,578 |
| Roflumilast | 28 | $4,733 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 127 | $2,727 |
| Wixela InhubFluticasone Propion/Salmeterol | 11 | $1,463 |
| Azelastine Hcl | 21 | $826 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $1,652 | $156,566240 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,615 | $70,843112 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $402 | $36,16659 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 354 critical care medicine providers in Pennsylvania.
Other critical care medicine in Media
- Briana DisilvioPittsburgh$204K
- Meilin YoungPittsburgh$182K
- Robert KruklitisAllentown$148K
- Lisa RathmanLancaster$86K
- Kees PoldermanPittsburgh$85K
- Pavan ThanguduHarrisburg$78K
- David DibardinoPhiladelphia$63K
- Harold PalevskyPhiladelphia$55K
- Steven KawutPhiladelphia$34K
- Michael RisbanoPittsburgh$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.